Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2
出版年份 2016 全文链接
标题
Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2
作者
关键词
Metastatic kidney cancer, High-dose interleukin-2, Survival outcomes, Clinical benefit, Immunotherapy
出版物
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 65, Issue 8, Pages 941-949
出版商
Springer Nature
发表日期
2016-06-09
DOI
10.1007/s00262-016-1854-1
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy
- (2017) Gary R. Hudes et al. Journal of the National Comprehensive Cancer Network
- Kidney Cancer, Version 3.2015
- (2015) Robert J. Motzer et al. Journal of the National Comprehensive Cancer Network
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2
- (2015) Michael KK Wong et al. Journal for ImmunoTherapy of Cancer
- Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program
- (2014) Roxanne Payne et al. Journal for ImmunoTherapy of Cancer
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
- (2013) Daniel YC Heng et al. LANCET ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibiting Systemic Autophagy during Interleukin 2 Immunotherapy Promotes Long-term Tumor Regression
- (2012) X. Liang et al. CANCER RESEARCH
- Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
- (2012) Laurence Albiges et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma
- (2010) Brian I. Rini CANCER
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005)
- (2008) Arie S. Belldegrun et al. CANCER
- High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma
- (2008) Jacob A. Klapper et al. CANCER
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started